Q3 Earnings Forecast for Sanofi Issued By Leerink Partnrs

Sanofi (NASDAQ:SNY) – Analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for Sanofi in a note issued to investors on Monday, January 27th. Leerink Partnrs analyst D. Risinger anticipates that the company will earn $1.57 per share for the quarter. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Leerink Partnrs also issued estimates for Sanofi’s Q4 2025 earnings at $0.91 EPS and FY2029 earnings at $5.88 EPS.

Separately, StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th.

Sanofi Stock Performance

NASDAQ:SNY opened at $52.37 on Wednesday. The company’s 50-day moving average is $48.99 and its two-hundred day moving average is $52.22. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market capitalization of $132.92 billion, a price-to-earnings ratio of 26.72, a PEG ratio of 1.19 and a beta of 0.57.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SNY. Jennison Associates LLC increased its position in shares of Sanofi by 938.0% in the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after purchasing an additional 1,720,972 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Sanofi by 28,890.2% during the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after purchasing an additional 1,424,289 shares in the last quarter. DAVENPORT & Co LLC increased its holdings in Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after buying an additional 664,455 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after buying an additional 399,301 shares in the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after buying an additional 395,744 shares during the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.